McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson Corporation (NYSE:MCK) has announced it will purchase Precision Medicine Group in a $2.25 billion deal as it strengthens its higher-growth businesses. The company has been focusing on oncology and specialty care, exiting non-core assets, and streamlining operations. Precision Medicine Group, based in Bethesda, Maryland, offers clinical research, laboratory testing, and commercialization services to biopharma companies.

The acquisition will enhance McKesson's clinical research and commercialization services, improve trial execution, and broaden its service offerings. CEO Brian Tyler highlighted the deal as a strategic extension of McKesson's growth strategy, rather than a hasty acquisition. The Oncology & Multispecialty segment, which includes the Precision Medicine Group, has shown strong growth, with revenue increasing 33% to $14.2 billion in the first quarter of fiscal 2026.

Analysts believe the acquisition will strengthen McKesson's biopharma offerings, but they raise questions about scalability and synergy creation. The deal is seen as a modest addition to McKesson's overall scale and is expected to contribute to growth gradually through the Oncology & Multispecialty segment.